Galmed's Aramchol Shows Anti-Fibrotic Effects In Lung Fibrosis Animal Model

Galmed Pharmaceuticals Ltd  (NASDAQ: GLMD ) announced results showing significant effects  of Aramchol in a preclinical lung and gastrointestinal (GI) fibrosis model. Treatment with Aramchol resulted in statistically significant improvement in a validated bleomycin model of lung fibrosis (IPF), comparable to Pirfenidone, the gold standard ... Full story available on Benzinga.com